US Cell Therapy Market

ID: MRFR/LS/18062-HCR
100 Pages
Satyendra Maurya
Last Updated: April 24, 2026
United States Cell Therapy Market Research Report: Size, Share, Trend Analysis By Types (Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy) By End Users (Hospitals, Research Institutions, Ambulatory Surgical Centers) By Applications (Oncology, Cardiovascular Disease, Neurological Disorders, Orthopedic Disorders) By Delivery Method (Intravenous Injection, Subcutaneous Injection, Intradermal Injection, Intramuscular Injection) - Growth Outlook & Industry Forecast 2025 To 2035
US Cell Therapy Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)8.58%
2024 Market Size$ 4,519.2 Million
2025 Market Size$ 4,906.95 Million
2035 Market Size$ 11,179 Million
Key Players
Novartis
Gilead Sciences
Bristol-Myers Squibb
Amgen
Celgene
Sangamo Therapeutics
Trends
  • Advancements in Manufacturing Techniques
  • Regulatory Support and Streamlining
  • Focus on Personalized Medicine
Opportunities
  • Supportive Reimbursement Policies
  • Growing Patient Awareness and Demand
  • Rising Prevalence of Chronic Diseases
Summary Table of Contents Segmentation Download PDF
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Pharmaceutical, BY Application (USD Million) | |
      1. 4.1.1 Oncology | |
      2. 4.1.2 Cardiovascular Disease | |
      3. 4.1.3 Neurological Disorders | |
      4. 4.1.4 Orthopedic Disorders |
    2. 4.2 Pharmaceutical, BY Type (USD Million) | |
      1. 4.2.1 Autologous Cell Therapy | |
      2. 4.2.2 Allogeneic Cell Therapy | |
      3. 4.2.3 Stem Cell Therapy |
    3. 4.3 Pharmaceutical, BY Delivery Method (USD Million) | |
      1. 4.3.1 Intravenous Injection | |
      2. 4.3.2 Subcutaneous Injection | |
      3. 4.3.3 Intradermal Injection | |
      4. 4.3.4 Intramuscular Injection |
    4. 4.4 Pharmaceutical, BY End User (USD Million) | |
      1. 4.4.1 Hospitals | |
      2. 4.4.2 Research Institutions | |
      3. 4.4.3 Ambulatory Surgical Centers 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Pharmaceutical | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Novartis (CH) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Gilead Sciences (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Bristol-Myers Squibb (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Amgen (US) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Celgene (US) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Sangamo Therapeutics (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Bluebird Bio (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Celyad Oncology (BE) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Fate Therapeutics (US) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 US MARKET ANALYSIS BY APPLICATION |
    6. 6.3 US MARKET ANALYSIS BY TYPE |
    7. 6.4 US MARKET ANALYSIS BY DELIVERY METHOD |
    8. 6.5 US MARKET ANALYSIS BY END USER |
    9. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL |
    10. 6.7 RESEARCH PROCESS OF MRFR |
    11. 6.8 DRO ANALYSIS OF PHARMACEUTICAL |
    12. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL |
    13. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL |
    14. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL |
    15. 6.12 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE) |
    16. 6.13 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Million) |
    17. 6.14 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE) |
    18. 6.15 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million) |
    19. 6.16 PHARMACEUTICAL, BY DELIVERY METHOD, 2024 (% SHARE) |
    20. 6.17 PHARMACEUTICAL, BY DELIVERY METHOD, 2024 TO 2035 (USD Million) |
    21. 6.18 PHARMACEUTICAL, BY END USER, 2024 (% SHARE) |
    22. 6.19 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Million) |
    23. 6.20 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    24. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    25. 7.2 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.2.2 BY TYPE, 2025-2035 (USD Million) | |
      3. 7.2.3 BY DELIVERY METHOD, 2025-2035 (USD Million) | |
      4. 7.2.4 BY END USER, 2025-2035 (USD Million) |
    26. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.3.1 |
    27. 7.4 ACQUISITION/PARTNERSHIP | |

US Cell Therapy Market Segmentation

US Cell Therapy Market By Application (USD Million, 2025-2035)

  • Oncology
  • Cardiovascular Disease
  • Neurological Disorders
  • Orthopedic Disorders

US Cell Therapy Market By Type (USD Million, 2025-2035)

  • Autologous Cell Therapy
  • Allogeneic Cell Therapy
  • Stem Cell Therapy

US Cell Therapy Market By Delivery Method (USD Million, 2025-2035)

  • Intravenous Injection
  • Subcutaneous Injection
  • Intradermal Injection
  • Intramuscular Injection

US Cell Therapy Market By End User (USD Million, 2025-2035)

  • Hospitals
  • Research Institutions
  • Ambulatory Surgical Centers

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.